Raley’s Family of Fine Stores Issues Allergy Alert on Undeclared Cashew and Almond in Raley’s Frozen Sweet Pumpkin Ravioli

WEST SACRAMENTO, CA – Raley’s Family of Fine Stores removed Raley’s Frozen Sweet Pumpkin Ravioli 10 oz.from our Raley’s, Bel Air and Nob Hill stores on November 17, 2015. According to the manufacturer, the product may contain an undeclared cashew and almond allergen.
Read The Complete Story!

FDA approves first seasonal influenza vaccine containing an adjuvant

The U.S. Food and Drug Administration today approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.

FDA approves Portrazza to treat advanced squamous non-small cell lung cancer

The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

Mi Tienda Issues Precautionary Recall: Recall Affects Masa and Tostadas Purchased ONLY at Mi Tienda #1 Located at 1630 Spencer Highway, South Houston, TX

Mi Tienda, committed to high-quality products, is issuing a precautionary recall for masa and tostadas produced in-store and packed on Monday, November 16 and Tuesday, November 17 only at the Mi Tienda #1 store located at 1630 Spencer Highway, South Houston, TX. The precautionary recall is due to the possible presence of metal fragments in the Masa Preparada by the pound, Tostadas Botoneras Rojas and Tostadas Siveria Large Tostadas.

FDA approves vaccine for use after known or suspected anthrax exposure

The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine’s new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure.

FDA approves vaccine for use after known or suspected anthrax exposure

The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine’s new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure.